426 results on '"Legnani, Cristina"'
Search Results
2. More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
3. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events
4. D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results
5. Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
6. D-Dimer Levels in Patients with Acute Venous Thromboembolism and Occult Cancer: TheDd-Neo Study
7. MORE EARLY BLEEDS ASSOCIATED WITH HIGH BASELINE DIRECT ORAL ANTICOAGULANT LEVELS IN ATRIAL FIBRILLATION: THE MAS STUDY
8. D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
9. Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis
10. Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism
11. Sex Differences in Clinical Presentation of Lower Extremity Deep Vein Thrombosis.
12. LOW LEVELS OF DIRECT ORAL ANTICOAGULANTS AT STEADY STATE IN ATRIAL FIBRILLATION PATIENTS WHO LATER DEVELOP THROMBOTIC COMPLICATIONS; THE PROSPECTIVE MAS (MEASURE AND SEE) STUDY
13. D-dimer in diagnosis and prevention of venous thrombosis: recent advances and their practical implications
14. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
15. Fibrinolysis and Obesity
16. Venous Thromboembolism in Women of Childbearing Age: Insights from the START Registry
17. La ricerca del lupus anticoagulant: raccomandazioni del gruppo di studio sulla coagulazione di SIPMeL
18. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant
19. Evaluation of Coaguchek®Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study
20. COVID-19 pandemic affects the ability of negative D-dimer to identify venous thromboembolism patients at low risk of recurrence: insights from Apidulcis study
21. Linee guida SIPMeL per la ricerca dei polimorfismi nella diagnostica di screening della trombofilia
22. D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome
23. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum)
24. Evaluation of the prevalence of severe hyperhomocysteinemia in adult patients with thrombosis who underwent screening for thrombophilia
25. Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms
26. Thrombotic burden, D-dimer levels and complete compression ultrasound for diagnosis of acute symptomatic deep vein thrombosis of the lower limbs
27. G1691A factor V and G20210A FII mutations, acute ischemic stroke of unknown cause, and patent foramen ovale
28. Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor
29. Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results
30. Long-term Risk of Recurrent Venous Thromboembolism Among Patients Receiving Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism
31. Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia
32. Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies
33. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study
34. Multicenter evaluation of a new quantitative highly sensitive D-dimer assay, the Hemosil® D-dimer HS 500, in patients with clinically suspected venous thromboembolism
35. Membrane binding and anticoagulant properties of protein S natural variants
36. Thrombophilia testing in the real-world clinical setting of thrombosis centres taking part in the Italian Start 2-Register
37. Management and Outcomes of Isolated Distal Deep Vein Thromboses: A Questionable Trend toward Long-Lasting Anticoagulation Treatment. Results from the START-Register
38. Value Of Family History In Identifying Women At Risk Of Venous Thromboembolism During Oral Contraception: Observational Study
39. How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study
40. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: A prospective, randomised study comparing two doses of parnaparin (BAFLUX STUDY)
41. Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)
42. Age and gender specific cut-off values to improve the performance of d-dimer assays to predict the risk of venous thromboembolism recurrence
43. A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms
44. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis
45. Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism
46. Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study
47. Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register
48. D-dimer testing to determine the duration of anticoagulation therapy
49. Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register
50. Thrombocytopenia during fondaparinux prophylaxis: HIT or something different?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.